Bavarian Nordic has been granted a patent for an expression cassette that enhances the expression of a heterologous gene, specifically the Brachyury antigen. The cassette is part of a viral vector, such as a poxvirus, and encodes a fusion protein with the FPV 088 antigen. GlobalData’s report on Bavarian Nordic gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Bavarian Nordic AS - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Bavarian Nordic, Recombinant viral vaccines was a key innovation area identified from patents. Bavarian Nordic's grant share as of September 2023 was 47%. Grant share is based on the ratio of number of grants to total number of patents.

Enhancing expression of a heterologous gene using promoters and expression cassettes

Source: United States Patent and Trademark Office (USPTO). Credit: Bavarian Nordic AS

A recently granted patent (Publication Number: US11753652B2) discloses an expression cassette that includes a specific nucleic acid sequence (SEQ ID NO:6) linked to a nucleic acid sequence encoding a Brachyury antigen. This expression cassette results in the production of a fusion protein that combines the FPV 088 antigen with the Brachyury antigen. The fusion protein's amino acid sequence is specified as SEQ ID NO:23.

The expression cassette described in claim 1 can also include other nucleic acid sequences, such as SEQ ID NO:7, SEQ ID NO:8, or SEQ ID NO:9. Additionally, the specific nucleic acid sequence encoding the Brachyury antigen can be SEQ ID NO:12.

Furthermore, the patent includes two additional expression cassettes, one comprising the nucleic acid sequence of SEQ ID NO:72 and another comprising the nucleic acid sequence of SEQ ID NO:73.

The patent also covers a fowlpox viral vector that incorporates the expression cassette described in claim 1. This viral vector can be used to deliver and express the fusion protein in a host organism.

Overall, this granted patent provides a novel expression cassette that encodes a fusion protein combining the FPV 088 antigen and the Brachyury antigen. The patent also includes alternative nucleic acid sequences and a fowlpox viral vector incorporating the expression cassette. This technology has potential applications in various fields, including biotechnology and medicine, where the fusion protein may have therapeutic or diagnostic uses.

To know more about GlobalData’s detailed insights on Bavarian Nordic, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies